Navigation Links
invivodata Announces ePROficiency 2009 Web Seminar Series
Date:6/9/2009

Five Complimentary Webinars to Showcase Case Studies and Patient Reported Outcome Strategies

PITTSBURGH, June 9 /PRNewswire/ -- invivodata inc., the industry leader in electronic patient reported outcomes (ePRO) solutions and services for global clinical research, today announced its 2009 ePROficiency(TM) Web seminar series on Patient Reported Outcomes (PRO).

The webinar series is a continuation of invivodata's educational initiative which focuses on recent regulatory and industry trends related to PROs. Each of the series' five webinars is derived from presentations that were delivered by industry experts during invivodata's recently concluded ePROficiency Conference in Naples, FL.

Each complimentary webinar will feature international pharmaceutical researchers delivering insight on specific aspects of PRO in clinical research and answering questions on topics including:

  • Improving Measure Sensitivity in Early Stage Research - June 18
  • A Conceptual Model in the Context of a Global Drug Development Program - July 30
  • Developing PROs: Common Pitfalls & Recent Experiences - September 10
  • Supporting Regulatory Submissions and Inspections: the ePRO Perspective - October 22
  • eDiaries: From Clinical Proof-of-Concept through to NDA Approval - December 3

"We've always been very pleased with the response to our webinar programs, which represents the growing interest we've seen in PROs for clinical research," said Dr. Jean Paty, chief scientist and regulatory advisor at invivodata's consulting division, PRO Consulting(R). Considering the evolving use of PROs and its regulatory implications, it's no surprise that so many global trial sponsors are eager to learn more about the latest PRO strategies and trends."

To register for any of the webinars or to see a complete schedule of upcoming invivodata events, please visit http://www.invivodata.com/eweb/.

About invivodata inc.

invivodata combines behavioral science, information technology, and clinical research expertise to capture high quality clinical trial data directly from patients. invivodata's electronic Patient Reported Outcomes (ePRO) solutions, which are based on over 20 years of research, deliver reliable patient self-reported data by driving patient compliance with the protocol and eliminating recall biases that plague paper-based self-report data. invivodata's solutions include comprehensive trial-support services that facilitate the collection of ePRO data, web-based access to study data and operational reports that give researchers and sponsors visibility into study progress, and scientific and regulatory consulting on the use of PRO data in a regulated environment. invivodata's solution has been used in more than 275 clinical programs and is the industry-leading ePRO system in delivering primary efficacy data for FDA drug approvals. invivodata inc. is a privately held company with global headquarters in Pittsburgh, Pa., USA; its European headquarters is in London, England; and its technology development center is in Scotts Valley, Calif., USA. For more information visit www.invivodata.com.

    For more information, contact:

    invivodata inc.
    Christine Tobin
    Corporate Communications Specialist
    (412) 390-3000, ext. 3502
    ctobin@invivodata.com


'/>"/>
SOURCE invivodata inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. invivodata and PRO Consulting to Present at International Industry Events
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
(Date:6/22/2016)... , June 22, 2016 Cell Applications, ... allow them to produce up to one billion ... lot within one week. These high-quality, consistent stem ... preparing cells and spend more time doing meaningful, ... a proprietary, high-volume manufacturing process that produces affordable, ...
Breaking Biology Technology:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
Breaking Biology News(10 mins):